Home » AASTROM 3Q LOSS WIDENS 37 PERCENT
AASTROM 3Q LOSS WIDENS 37 PERCENT
Aastrom Biosciences Inc., which develops stem cell-based tissue-regeneration products, said Wednesday its third-quarter loss widened 37 percent as expenses increased, and announced it can now start
making products at its German plant.
The Houston Chronicle
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
02May
-
07May
-
14May
-
23May
-
30May